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New vitamin D analogs. absorption and bone calcium mobilization, however, can
Background. 1,25-(OH)2D3 (calcitriol) controls parathyroid lead to hypercalcemia, often precluding 1,25-(OH)2D3
gland growth and suppresses the synthesis and secretion of therapy. Hyperphosphatemia is also a persistent problemparathyroid hormone. Because of this, 1,25-(OH)2D3 has been in these patients and can only be aggravated by the useused successfully for the treatment of secondary hyperparathy-
of 1,25-(OH)2D3 [9, 10]. In addition, the use of calciumroidism, which almost always accompanies renal failure. How-
ever, the potent effect of 1,25-(OH)2D3 on intestinal calcium salts as phosphate binders only increases the risk of the
and phosphorus absorption and bone mineral mobilization of- development of hypercalcemia during 1,25-(OH)2D3
ten leads to the development of hypercalcemia and hyperphos- treatment [11–12].phatemia precluding 1,25-(OH)2D3 therapy. The risk of hypercalcemia, as well as hyperphosphate-Methods. This has led to the development of vitamin D
mia brought on by 1,25-(OH)2D3 therapy, spurred theanalogs that retain the suppressive action on PTH and parathy-
roid gland growth, but that have less calcemic and phos- development of less calcemic and phosphatemic analogs
phatemic activity. Currently, two analogs, 19-nor-1,25-(OH)2D2 of 1,25-(OH)2D3. The ideal analog for the treatment of
and 1,(OH)D2, are being used for the treatment of secondary SH would be at least as potent as 1,25-(OH)2D3 in sup-hyperparathyroidism in the United States, and two are being
pressing PTH, but would have a minimal effect on cal-used in Japan, 22-oxa-calcitriol and 1,25-(OH)2-26,27F6 D3.
cium and phosphorus metabolism.Results. All four analogs suppressed PTH, but had less cal-
cemic and phosphatemic activity than 1,25-(OH)2D3. In rats, The biological actions of 1,25-(OH)2D3 are mediated
19-nor-1,25-(OH)2D2 has been shown to be less calcemic and through the vitamin D receptor (VDR). The binding of
phosphatemic compared to 1,(OH)D2. 1,25-(OH)2D3 to the VDR results in a conformationalConclusion. Therapeutic doses of 19-nor-1,25-(OH)2D2 change in the VDR which allows it to also bind to thecould produce a lower Ca x P product compared to 1,(OH)D2,
retinoid X receptor (RXR). The binding of this VDR/which could be an important consideration in patient treat-
ment. Further studies are necessary to define these differences RXR complex to a specific sequence in the vitamin
and to understand the mechanisms behind the differential ac- D-responsive element (VDRE) increases or decreases
tions of vitamin D analogs. gene transcription.
Since there is evidence for only one form of nuclear
VDR, it is assumed that the classic actions (calcemic)
Secondary hyperparathyroidism (HPT), a universal and nonclassic actions (potentially therapeutic) are both
complication of renal failure, is characterized by en- mediated through the same VDR. One intriguing aspect
larged parathyroid glands and an increase in parathyroid of the newly developed analogs is their differential action
hormone (PTH) synthesis and secretion. Key factors in vivo compared to1,25-(OH)2D3. It would be expectedin the development of SH are abnormalities in 1,25- that these new analogs would mimic the actions of 1,25-
(OH)2D3 production and metabolism, a decrease in the (OH)2D3 since most have a high affinity for the VDR,number of vitamin D receptors (VDR), and a resistance but their novel feature is their ability to support some,
to the actions of 1,25-(OH)2D3, all of which occur as but not all, of the actions of 1,25-(OH)2D3. While theyrenal failure progresses. 1,25-(OH)2D3, the most active are potent suppressors of PTH, the analogs usually show
metabolite of vitamin D, controls parathyroid gland a decreased potency in the intestine and bone, which
growth and suppresses the synthesis and secretion of results in decreased calcemic and phosphatemic re-
PTH [1–4]. Because of its effect on PTH, 1,25-(OH)2D3 sponses. This selectivity has also been shown with vita-
has been successfully used for the treatment of SH [5–8]. min D analogs developed for other therapeutic uses, such
The potent effects of 1,25-(OH)2D3 on intestinal calcium as psoriasis, immunomodulation, leukemia, and other
cancers [13, 14]. Interestingly, the selectivity of these
analogs is not always cell- or tissue-specific, but can beKey words: uremia, hyperparathyroidism, calcium, phosphorus, caci-
triol. gene- or process-specific within the same tissue.
The relationship of the structure of a vitamin D com- 2003 by the International Society of Nephrology
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Fig. 1. Chemical structure of 1,25(OH)2D3 and several vitamin D analogs. (Reproduced from reference [29]).
pound to its activity has been studied in detail [15]. Most carbon 19 and the exocyclic double bond. In early stud-
ies, we found that 19-nor-1,25-(OH)2D2 had the samecritical for binding to the VDR is the A-ring, especially
in the hydroxyl groups. While modifications in the D- potency as 1,25-(OH)2D3 in suppressing PTH secretion
in primary cultures of bovine parathyroid cells and couldring or the side chain have little effect on VDR binding,
they can affect biologic activity by altering the pharmaco- suppress pre-pro-PTH messenger RNA and PTH secre-
tion without inducing hypercalcemia or hyperphosphate-kinetics or catabolism of the compound. Analogs can
also produce distinct conformational changes in the mia [16]. When given daily to parathyroidectomized rats
fed either a calcium- or phosphorus-deficient diet forVDR that may produce gene-specific actions. Thus, a
combination of structural modifications can produce ana- nine days, 19-nor-1,25-(OH)2D2 generated smaller in-
creases in plasma calcium and phosphorus than did 1,25-logs with diverse biologic profiles.
(OH)2D3 [17]. In fact, additional dose-response studies
Selective vitamin D analogs for the treatment of SH showed 19-nor-1,25-(OH)2D2 to be about 10 times less
potent in mobilizing calcium and phosphorus from boneThere are several requirements for vitamin D analogs
developed for the treatment of SH. First, the analog has than 1,25-(OH)2D3. Moreover, in contrast to 1,25-(OH)2D3,
which upregulates intestinal VDR, 19-nor-1,25-(OH)2D2to have a reasonable affinity for the VDR. As earlier
noted, this requires the presence of a hydroxyl group in had the opposite effect [18]. In an early trial in renal
patients (Fig. 2), 19-nor-1,25-(OH)2D2 was given at athe 1 position. Second, the analog needs to be substan-
tially less calcemic than the parent compound. Despite a graded dose of 0.04 g/kg to 0.12 g/kg over a seven-
week period [19]. At the end of the study, plasma PTHhigh affinity for the VDR, many analogs have significantly
less calcemic activity than 1,25-(OH)2D3. An example of levels had decreased an average of 60%. In addition,
only seven incidences of hypercalcemia occurred out ofthis is 19-nor-1,25-(OH)2D2, which is approximately 10
times less calcemic than 1,25-(OH)2D3. The decreased 441 determinations. In each of these incidences PTH
levels were decreased to less than 100 pg/mL, presumablycalcemic activity of 19-nor-1,25-(OH)2D2 cannot be at-
tributed to decreased VDR binding. Finally, the analog as a result of the hypercalcemia. Thus, hypercalcemia
was likely due to an excessive dose of 19-nor-1,25-(OH)2D2.has to be able to suppress PTH in vivo. Although some
analogs were effective in suppressing PTH in vitro, when Since it is recommended that plasma PTH levels be main-
tained between 200 and 300 pg/mL to maintain normaltested in vivo, they were rapidly metabolized and not
effective in treating SH. Four analogs are currently used bone histology, a lower dose of 19-nor-1,25-(OH)2D2
could have been given, minimizing the likelihood of fur-for the treatment of SH, 19-nor-1,25-(OH)2D2 (paricalci-
tol, Zemplar) and 1-(OH)D2 (doxercalciferol, Hec- ther hypercalcemic episodes. More recent metabolic
studies in rats comparing 19-nor-1,25-(OH)2D2 and 1torol), in the United States, and 22-oxa-calcitriol (OCT)
and 1,25-(OH)2-26,27F6 D3 (falecalcitriol), in Japan. The (OH)D2 showed 19-nor-1,25-(OH)2D2 to be less calcemic
and phosphatemic than 1,(OH)D2 [20]. While bothchemical structures of the first three compounds are
shown in Figure 1. compounds suppressed PTH, therapeutic doses of 19-
nor-1,25-(OH)2D2 resulted in a lower Ca x P productWe have extensively studied 19-nor-1,25-(OH)2D2. As
with all vitamin D2 compounds, this analog has a carbon compared to 1,(OH)D2. With our increasing under-
standing of the deleterious effects of vascular calcifica-28 and a double bond at the carbon 22 position. However,
unlike all natural vitamin D compounds, it lacks the tion on mortality and morbidity in the dialysis popula-
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Mechanisms for the differential actions of
1,25-(OH)2D3 and its analogs
The possible steps in the vitamin D pathway where
differences in vitamin D analog action could lead to
selective activities in vivo are shown in Fig. 3. The first
of these is DBP affinity. The major carrier of vitamin
D compounds in the circulation is the serum DBP. A
decreased affinity for the DBP results in the analog being
cleared faster from the circulation and thus, a shorter
half-life. While this may explain the differential action
of OCT, since its affinity for the DBP is 400 to 500 times
less than that of 1,25-(OH)2D3, it does not explain that
of 19-nor-1,25-(OH)2D2 or 1,25-(OH)2D2, the active me-Fig. 2. Changes in the levels of intact PTH expressed as the percentage
tabolite of 1(OH)D2, since their affinities for the DBPof the change from baseline values during the study period in placebo-
treated () and 19-nor-1,25(OH)2D2-treated () patients. The bars are similar to 1,25-(OH)2D3.
depict the doses of 19-nor-1,25(OH)2D2 that increase according to the In addition to enhancing the circulating half-life of
protocol. (Reproduced from reference [19]).
vitamin D compounds, the DBP also decreases the tissue
accessibility of 1,25-(OH)2D3. In this way, DBP helps to
protect against vitamin D intoxication. Analogs with a
tion, this could be an important consideration in patient decreased affinity for the DBP, although more quickly
treatment. cleared from the circulation, may have increased tissue
1(OH)D2 is a pro-hormone and must be converted uptake. This could result in tissue-specific responses by
in the liver to its active metabolite, 1,25(OH)2D2. While increasing the response in tissues that require only a
this compound is less calcemic than 1,25-(OH)2D3, the short exposure for a sustained response, while having
basis for this is not well understood. While early studies little effect on tissues requiring long-term exposure to a
comparing 1(OH)D2 and 1(OH)D3 showed 1(OH)D2 vitamin D compound in order to sustain an effect.
to be less toxic, the two compounds displayed the same Besides DBP, other proteins in circulation such as
potency in intestinal calcium transport and bone calcium albumin and lipoproteins may bind small amounts of
mobilization [21, 22]. The effectiveness of 1(OH)D2 natural vitamin D compounds, but with lower affinity.
administered both orally and intravenously (IV) in the While 99% of 1,25-(OH)2D3 in circulation is proteintreatment of SH has been demonstrated [23, 24]. Intrave- bound, mostly to DBP, other proteins may play a role
nous administration of 1(OH)D2 produced smaller in- in transporting analogs that have less affinity for the
crements in serum calcium and phosphorus than oral
DBP. The impact, if any, of this on the differential actions
dosing [23]. However, the prevalence of hypercalcemia
of vitamin D analogs is not known.and hyperphosphatemia were still high with IV therapy.
Target cell metabolism plays an important role in sev-22-Oxacalcitriol, or OCT, differs from 1,25-(OH)2D3 eral steroid hormone systems. Vitamin D compoundsonly by the substitution of an oxygen atom in place
are primarily metabolized by the vitamin D-24-hydroxy-of the carbon 22 in the side chain. Compared to 1,25-
lase. Modifications in the side chains of some analogs(OH)2D3, the affinity of OCT for the VDR and vitamin
may result in a different rate of catabolism, resulting inD-binding protein (DBP) are 8 and 400 to 500 times
longer or shorter exposures of the analog to the tissue,less, respectively. This alone could account for its lower
or may result in different metabolites which may affectactivity in the intestine and bone. OCT is cleared rapidly
vitamin D action. Indeed, both of these have been shownfrom the circulation, which is probably secondary to its
to account, at least in part, for the unique properties oflow DBP affinity. Previous studies demonstrated that a
several vitamin D analogs.short exposure of the parathyroid glands to OCT leads
A decreased affinity for the VDR may cause a de-to a prolonged suppression of PTH, while the stimulation
creased or blunted response by a vitamin D analog com-of intestinal calcium absorption and bone resorption is
pared to the parent compound. While this may accountshort lived [25]. This could explain why OCT can sup-
in part for the differential actions of OCT, whose affinitypress PTH yet have decreased calcemic and phospha-
for the VDR is about eight times less than that of 1,25-temic activities.
(OH)2D3, again, it does not explain the disparate actions1,25-(OH)226,27F6 D3, or falecalcitriol, is an analog in
of 19-nor-1,25-(OH)2D2 or 1,25-(OH)2D2, since their af-which carbons 26 and 27 are replaced by fluorine atoms.
finities for the VDR are similar to 1,25-(OH)2D3.This analog is metabolized more slowly than 1,25-
Upon binding to the VDR, 1,25-(OH)2D3 produces a(OH)2D3, which accounts for its higher activity in vivo
[26, 27]. specific conformational change in the VDR that allows
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OCT compared to 1,25-(OH)2D3, little is known about
the mechanisms behind the selective actions of 19-nor-
1,25-(OH)2D2 or 1,(OH)2. Better understanding of
these mechanisms could provide insight for the design
and development of more effective analogs in the future.
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